

HemoPore®

Hemostatic Bioresorbable Nasal Dressing

Stabilization plus hemostatic control

With firm compression strength and the hemostatic agent chitosan lactate, HemoPore bioresorbable nasal dressing provides two forms of post-op hemostatic control. The result is reliable tissue support and fluid absorption that helps avoid the need for separate topical hemostats.



Support you need


hemostatic control you want

HemoPore bioresorbable nasal dressing delivers all the qualities you like in NasoPore® dressings, plus the added clinical benefits of the hemostatic agent chitosan lactate. Its firm compression strength also aids hemostasis, and helps prevent adhesions and minimize edema while maintaining structure separation and stabilization.

- 10-14 day fragmentation time¹
- 36-48 hours tissue support/shape integrity¹
- Absorbs an average of 20x its weight (+/-8) without swelling in size
- Clears through natural mucosal flow
- No mixing, moistening, injection syringes or other prep needed

Chitosan lactate

- Spurs resting platelets into activation; helping them adhere to collagen³⁻⁵
- Fosters platelet aggregation; forming platelet plugs that accelerate blood coagulation^{3,5-7}
- Has inherent anti-microbial properties³



▲ *In vitro* findings showed HemoPore dressings prompted higher platelet activation and aggregation than similar hemostatic products and NasoPore Firm, thus accelerating blood coagulation and healing.²

Error bars are representative of standard error of the mean.

Ordering is easy

Part Number: 5400-020-208 (8 per pack; 8cm size)

All variations of our bioresorbable solutions are conveniently available through a single source. To order, call Customer Service at **800-253-3210** or contact your Stryker NSE sales representative. For more details visit

www.stryker.com/bioresorbables


References

1. Stryker internal performance data on file.
2. "Thrombogenic Performance of Stryker® HemoPore® Hemostatic Bioresorbable Nasal Dressing and Other Marketed Nasal Dressings." Stryker internal white paper, 9100-003-317 Rev None.
3. Bhaskara Rao S, Sharma CP. "Use of chitosan as a biomaterial: Studies on its safety and hemostatic potential." *J Biomedical Materials Res*. 1997; 34:21-28.
4. He Q, Gong K, Ao Q, Ma T, Yan Y, Gong Y, Zhang X. "Positive charge of chitosan retards blood coagulation on chitosan films." *J Biomaterials Applications* 2011; 27(8):1032-45.
5. Chou T, Fu E, Wu C, Yeh J. "Chitosan enhances platelet adhesion and aggregation." *Biochem. Biophys. Res. Commun.* 2003; 302:480-83.
6. Wu C, Ko F, Huang T, Teng C. "Mechanisms-regulated platelet spreading after initial platelet contact with collagen." *Biochem. Biophys. Res. Commun.* 1996; 220:388-93.
7. Jobling J, Eyre L. "Haemostasis, blood platelets and coagulation." *Anaesthesia Intensive Care Med.* 2013; 14 (2):51-53.
8. Dai, T, Huang, Y, Tanaka, M "Chitosan preparations for wounds and burns: antimicrobial and wound-healing effects." *National Institute of Health.* 2011; 9(7):857-879.

The information presented in this brochure is intended to demonstrate the breadth of Stryker product offerings. Always refer to the package insert, product label and/or user instructions before using any Stryker product. Products may not be available in all markets. Product availability is subject to the regulatory or medical practices that govern individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area.

Products referenced with TM designation are trademarks of Stryker. Products referenced with ® designation are registered trademarks of Stryker.

Literature Number: 9100-003-406 Rev None G55

 See HemoPore Instructions for Use (IFU) for complete details.

HemoPore should not be used in patients who have known allergies to shellfish.

Copyright © 2015 Stryker
Printed in USA

Stryker Neuro Spine ENT
4100 East Milham Avenue
Kalamazoo, MI 49001 USA
t: 269 323 7700 f: 800 999 3811
toll free: 800 253 3210

www.stryker.com/NSE